Vesugen
Vesugen is a synthetic tripeptide bioregulator (Lys-Glu-Asp) that modulates gene expression and protein synthesis, particularly through SIRT1 upregulation. It is investigated for supporting vascular endothelial function, neuroprotection, and decelerating cellular aging processes.
Vesugen is a Khavinson bioregulator tripeptide developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology. Composed of three amino acids (lysine, glutamic acid, aspartic acid), it targets the vascular system and protects blood vessels from age-related decline. Research shows it limits atherosclerosis development, decreases endothelial dysfunction, and activates stem cells. Like other short Khavinson peptides, Vesugen penetrates to the nucleus where it influences gene expression.
Mechanism of Action
Vesugen works through epigenetic regulation by interacting with DNA promoter regions, particularly affecting Ki-67 gene expression which controls cell division. It plays a prominent role in regulating sirtuin 1 (SIRT1) protein levels - a key anti-aging protein activated during calorie restriction. Vesugen enhances mesenchymal stem cell proliferation, reduces senescence markers, improves cell differentiation, and may reverse the Senescence-Associated Secretory Phenotype (SASP) implicated in age-related cardiovascular disease.
Reconstitution Calculator
Safety Profile
Safety Profile: Vesugen
Common Side Effects
- Injection site reactions: pain, redness, and mild swelling
- Mild headache
- Fatigue and mild malaise
- Mild gastrointestinal discomfort
Serious Adverse Effects
- Very limited published safety data; Vesugen is a tripeptide (Lys-Glu-Asp) from the Khavinson peptide bioregulator series
- No well-documented serious adverse events in available literature
- Theoretical vascular effects given its proposed mechanism (vascular endothelial support)
- Long-term safety profile completely unknown
- Allergic reactions possible as with any peptide
Contraindications
- Known hypersensitivity to Vesugen or related peptide bioregulators
- Active vascular thrombosis or hypercoagulable states (vascular-active peptide; effects unpredictable)
- Pregnancy and lactation (no safety data)
- Children (no pediatric data)
- Active cancer (angiogenic potential unknown)
Drug Interactions
- Anticoagulants and antiplatelets: Unknown effect on vascular function and coagulation
- Antihypertensives: Potential for additive or opposing vascular effects
- Other peptide bioregulators: Commonly combined in protocols; interactions unstudied
- No characterized CYP450 interactions
Population-Specific Considerations
- Primarily available in Russia: Very limited international availability and regulatory oversight
- Vascular health focus: Proposed to support vascular endothelial function; used in age-related vascular decline
- Elderly population: Primary target demographic
- Evidence quality: Published research predominantly in Russian-language journals; international peer review limited
- Not a substitute: Should not replace established cardiovascular medications or interventions
Pharmacokinetic Profile
- Half-life
- Not established
Quick Start
- Typical Dose
- 10-20 mg per day (oral capsules) or 10 mg (injectable)
- Frequency
- Daily for 10-20 consecutive days (Khavinson bioregulator cycle)
- Cycle Length
- 10-20 day cycle
- Storage
- Oral capsules: room temperature; Lyophilized powder/reconstituted: 2-8°C refrigerated
Molecular Structure
- Weight
- 390 Da
- Length
- 3 amino acids
Research Indications
Vascular Health
Protects blood vessels from age-related deterioration through gene expression regulation.
Limits development of atherosclerotic plaques in blood vessels.
Decreases endothelial dysfunction that contributes to cardiovascular disease.
Anti-Aging
Regulates sirtuin 1 levels, mimicking some benefits of calorie restriction.
Enhances mesenchymal stem cell proliferation and reduces senescence.
Reverses senescence-associated secretory phenotype in aging cells.
Research Protocols
subcutaneous Injection
Vascular bioregulator (Lys-Glu-Asp). Weekly titration to maintenance.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Week 1 | 500 mcg | Once daily | Week 1 |
| Week 2 | 1,000 mcg | Once daily | Week 2 |
| Week 3 | 1,500 mcg | Once daily | Week 3 |
| Maintenance | 1,500-2,000 mcg | Once daily | Weeks 4-8+(Cycle 8-12 weeks, extendable to 16) |
Reconstitution Guide (20mg vial + 3mL BAC water)
- Wipe vial tops with alcohol swab
- Draw 3.0 mL bacteriostatic water into syringe
- Inject slowly down the inside wall of the peptide vial
- Gently swirl to dissolve — never shake
- Resulting concentration: 6.67 mg/mL
- For 500 mcg dose: draw 7.5 units (0.075 mL)
- For 1,000 mcg (1 mg) dose: draw 15 units (0.15 mL)
- For 1,500 mcg dose: draw 22.5 units (0.225 mL)
- For 2,000 mcg (2 mg) dose: draw 30 units (0.30 mL)
- Store reconstituted vial refrigerated at 2-8°C
oral
Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles, often repeated 2-3 times per year.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| Standard protocol | 10-20 mg | Daily for 10-20 days | —(Route: Oral capsules) |
Interactions
Peptide Interactions
Complementary cardiovascular bioregulators - Vesugen for vessels, Cardiogen for heart tissue.
Often combined in comprehensive anti-aging Khavinson protocols.
Different organ targets; can be used in comprehensive bioregulator protocols.
Part of Khavinson bioregulator family; targets different tissue.
What to Expect
What to Expect
Gene expression modulation and SIRT1 activation begins
Effects persist due to epigenetic changes
Vascular function improvements
Cumulative benefits with periodic cycles
Safety Profile
Common Side Effects
- Generally well-tolerated
- Minimal side effects reported
Contraindications
- Active cardiovascular emergencies (seek medical care)
- Known hypersensitivity
- Pregnancy or breastfeeding
Discontinue If
- Allergic reactions
- Unusual cardiovascular symptoms
Quality Indicators
What to look for
- White powder or capsules
- Clear solution if reconstituted
- Proper packaging and labeling
Caution
- Unknown source or purity
Red flags
- Discoloration
- Unusual odor
- Damaged packaging
References (5)
- [1]Khavinson Peptide Bioregulators Research (2020)
- [2]Short Peptides and Vascular Aging (2018)
- [3]Mesenchymal Stem Cell Activation by Peptide Bioregulators (2019)
- [4]Khavinson VKh, Morozov VG Peptides of pineal gland and thymus prolong human life Neuro Endocrinol Lett (2003)
→ Khavinson peptide bioregulators dosed as short repeated courses reduced mortality in elderly over long-term follow-up.
- [5]Khavinson VKh, Kuznik BI, Ryzhak GA Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies Adv Gerontol (2012)
→ Experimental review of short peptide bioregulators (including vascular peptides) increasing lifespan and regulating gene expression in animal models.
Vesilute
Vesilute is a Khavinson bioregulator dipeptide consisting of glutamic acid and aspartic acid (ED), developed at the St. Petersburg Institute of Bioregulation an
Vilon
**Vilon** (Lys-Glu, also designated KE dipeptide) is the shortest biologically active peptide in the Khavinson bioregulator series, consisting of just two amino